MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes
| Autor: | Elise Klæstad, Signe Opdahl, Monica J. Engstrøm, Elisabeth Wik, Borgny Ytterhus, Anna M. Bofin, Marit Valla |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Adult Ribosomal Proteins Cancer Research DNA Copy Number Variations Proliferation Amplification Breast Neoplasms Biology Mitochondrial Proteins 03 medical and health sciences Basal (phylogenetics) 0302 clinical medicine Breast cancer Preclinical Study Gene expression medicine Biomarkers Tumor MRPS23 Humans Cumulative incidence Registries Neoplasm Metastasis Lymph node In Situ Hybridization Fluorescence Aged Cell Proliferation Neoplasm Staging Aged 80 and over medicine.diagnostic_test Copy number Incidence Hazard ratio Middle Aged medicine.disease Chromosome 17 (human) Gene Expression Regulation Neoplastic 030104 developmental biology medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Cancer research Female Neoplasm Grading METABRIC Fluorescence in situ hybridization |
| Zdroj: | Breast Cancer Research and Treatment |
| Popis: | Purpose MRPS23 is recognized as a driver of proliferation in luminal breast cancer. The aims of the present study were to describe MRPS23 copy number change in breast cancer, and to assess associations between MRPS23 copy number change and molecular subtype, proliferation and prognosis, and between MRPS23 gene expression and molecular subtype and prognosis. Methods Using fluorescence in situ hybridization (FISH), we examined MRPS23 and centromere 17 copy number in 590 formalin-fixed, paraffin-embedded primary tumours and 144 corresponding lymph node metastases from a cohort of Norwegian breast cancer patients. Furthermore, we analysed MRPS23 gene expression data in 1971 primary breast cancer tumours from the METABRIC dataset. We used Pearson’s χ2 test to assess associations between MRPS23 copy number and molecular subtype and proliferation, and between MRPS23 expression and molecular subtype. We studied prognosis by estimating hazard ratios and cumulative incidence of death from breast cancer according to MRPS23 copy number and MRPS23 expression status. Results We found MRPS23 amplification (mean MRPS23 copy number ≥ 6 and/or MRPS23/chromosome 17 ratio ≥ 2) in 8% of primary tumours. Copy number increase associated with non-basal subtypes and higher tumour cell proliferation (Ki67). Higher MRPS23 expression associated with the Luminal B subtype. We found no significant association between MRPS23 amplification or MRSP23 gene expression, and prognosis. Conclusion Amplification of MRPS23 is associated with higher proliferation and non-basal subtypes in breast cancer. High MRPS23 expression is associated with the Luminal B subtype. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|